Navigation Links
Lymphoblastic Leukemia Survivors at Risk for Secondary Cancer

A new study finds that survivors of acute lymphoblastic leukemia have a significantly increased risk of secondary cancers when compared to the general population. //

Acute lymphoblastic leukemia is the most common cancer in children and adolescents, with almost 4,000 new cases diagnosed in the United States each year. It is also one of the most curable pediatric cancers: survival rates for patients who receive contemporary treatments now exceed 80 percent, and most of these survivors are cured (no evidence of disease for at least 10 years).

"Accordingly, characterization of long-term outcomes in acute lymphoblastic leukemia patients who remain in first complete remission for at least a decade has assumed increasing importance, especially in view of the long life expectancy of this survivor population." But little is known about the incidence of secondary tumors or cancer after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia.

Nobuko Hijiya, M.D., of St. Jude Children's Research Hospital, Memphis, Tenn., and colleagues conducted a study to estimate the long-term (30-year) cumulative incidence of secondary neoplasms (cancers) in 2,169 children and adolescents treated for acute lymphoblastic leukemia between 1962 and 1998 at St. Jude Children's Research Hospital. The patients had achieved complete remission and had a median (mid-point) follow-up time of 18.7 years (range, 2.4 - 41.3 years).

The researchers found that among the 1,290 patients who remained in complete remission, 123 (9.5 percent) developed a secondary neoplasm as their first event. The cumulative incidence of secondary neoplasms in all patients as the first event after complete remission was 4.17 percent at 15 years, increasing to 5.37 percent at 20 years and to 10.85 percent at 30 years. "The relatively rapid increase in incidence at 20 years after complete remission can be attributed largely to the late development of me ningiomas [a tumor near the brain and spinal cord] and basal cell carcinomas," the authors write.

When meningiomas and basal cell carcinomas were excluded, the overall cumulative incidence was 3.99 percent at 15 years and 6.27 percent at 30 years, representing a 13.5-fold increase in overall risk compared with the general population.

The cumulative incidence of each tumor type at 30 years was 2.19 percent for myeloid (related to bone marrow) malignancy, 0.17 percent for lymphoma, 3.00 percent for brain tumor, 4.91 percent for carcinoma, and 0.57 percent for sarcoma.

"In conclusion, the cumulative incidence of secondary neoplasm after treatment for childhood acute lymphoblastic leukemia does not attain a plateau at 15 to 20 years but continues to increase over 30 years. Although the majority of these late-occurring secondary neoplasms are low-grade tumors such as meningioma and basal cell carcinoma, the health care issues they raise may be critical. The risk for high-grade tumors, especially carcinomas, significantly exceeds the risk in the general population, underscoring the need for continued careful follow-up of acute lymphoblastic leukemia survivors," the authors write.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Gene Fusion Test to screen children’s with Acute Lymphoblastic Leukemi
2. Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate
3. Good And Evil Clones Of Acute Lymphoblastic Leukaemia cells
4. A New Treatment Discovered For Acute Lymphoblastic Leukemia
5. Cyclosporin A Treats Leukemia Complications
6. Leukemia pill shows promise against stomach cancer
7. Aspirin Lowers Leukemia Risk
8. Hope for Chemo-Resistant Leukemia Patients
9. Genes Found To Help Leukemia Treatment
10. Looking Towards More Effective Leukemia Treatment
11. Diet Found To Offer Protection Against Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , ... Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day ... at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: